Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors | Financial Post

Junshi Biosciences received FDA approval for its anti-CD112R monoclonal antibody (TAB009/JS009) to treat advanced solid tumors. This antibody targets CD112R, a new immune checkpoint, enhancing T and NK cells' ability to fight tumors. It shows synergistic effects with other treatments, aiming to maximize anti-tumor potential.